Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor Senicapoc in non-alcoholic liver disease

机译：KCa3.1通道抑制剂Senicapoc在非酒精性肝病中的抗硬脂化和抗纤维化作用

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

AIMTo evaluate a calcium activated potassium channel (KCa3.1) inhibitor attenuates liver disease in models of non-alcoholic fatty liver disease (NAFLD).

机译：目的在非酒精性脂肪肝疾病（NAFLD）模型中评估钙激活的钾通道（KCa3.1）抑制剂可减轻肝脏疾病。

著录项

期刊名称 World Journal of Gastroenterology
作者
Latha Paka; David E Smith; Dawoon Jung; Siobhan McCormack; Ping Zhou; Bin Duan; Jing-Song Li; Jiaqi Shi; Yong-Jie Hao; Kai Jiang; Michael Yamin; Itzhak D Goldberg; Prakash Narayan;
展开▼
作者单位

展开▼
年(卷),期 2017(23),23
年度 2017
页码 4181–4190
总页数 11
原文格式 PDF
正文语种
中图分类肠道病毒与肝炎病毒;肝及胆疾病;肠疾病;
关键词
High fat diet Liver Steatosis Fibrosis KCa3.1 channel Senicapoc Inflammation;

机译：高脂饮食;肝;脂肪变性;纤维化;KCa3.1通道;Senicapoc;炎症;

相似文献

外文文献
中文文献
专利

1. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease [J] . Latha Paka, David E Smith, Dawoon Jung, World Journal of Gastroenterology . 2017,第23期

机译：Kca3.1通道抑制剂Senicapoc在非酒精性肝病中的抗硬脂化和抗纤维化作用
2. Systems pharmacology-based exploration reveals mechanisms of anti-steatotic effects of Jiang Zhi Granule on non-alcoholic fatty liver disease [J] . Yiyuan Zheng, Miao Wang, Peiyong Zheng, Scientific reports. . 2018,第1期

机译：基于系统药理学的探索揭示了姜芝颗粒对非酒精性脂肪肝疾病的抗硬脂化作用的机制
3. Effects of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, and free omega-3 carboxylic acids on liver steatosis and hepatocyte damage biomarkers in Type 2 diabetes patients with non-alcoholic fatty liver disease [J] . Oscarsson Jan, Lundkvist Per, Jansson Per-Anders E., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：Dapagliflozin，钠葡萄糖共转运蛋白2抑制剂和自由ω-3羧酸对2型糖尿病患者非酒精性脂肪肝病患者的肝脏脂肪变性和肝细胞损伤生物标志物的影响
4. Development of Bioimpedance-based Measuring Systems for Diagnosis of Non-alcoholic Fatty Liver Disease [C] . Nina Gyorfi, Akos Odry, Zoltan Karadi, IEEE International Symposium on Applied Computational Intelligence and Informatics . 2021

机译：基于生物敏衡测量系统的开发，用于诊断非酒精性脂肪肝病
5. Metabolic syndrome in non-alcoholic fatty liver disease: A comparison between simple steatosis and non-alcoholic steatohepatitis [D] . Avand, Ghazal 2006

机译：非酒精性脂肪肝疾病的代谢综合征：单纯性脂肪变性和非酒精性脂肪性肝炎的比较
6. The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists [O] . Chan-Hee Jung, Ji-Oh Mok 2019

机译：降糖药对非酒精性脂肪性肝病的影响：集中于钠葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂。
7. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease [O] . Latha Paka, David E Smith, Dawoon Jung, 2017

机译：KCA3.1通道抑制剂，Senicapoc，在非酒精性肝病中的抗真菌和抗纤维化作用

Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor Senicapoc in non-alcoholic liver disease

摘要

著录项

相似文献

相关主题

期刊订阅